Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing

[1]  B. Bonanni,et al.  Response to Dominguez-Valentin M et al. 2019: Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[2]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[3]  D. Steinemann,et al.  The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants , 2019, International journal of cancer.

[4]  P. Møller,et al.  The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.

[5]  P. Møller,et al.  Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift , 2019, Cancers.

[6]  F. Couch,et al.  Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels , 2018, Genetics in Medicine.

[7]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[8]  C. Boland,et al.  Recent progress in Lynch syndrome and other familial colorectal cancer syndromes , 2018, CA: a cancer journal for clinicians.

[9]  C. Turnbull,et al.  Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group , 2018, Journal of Medical Genetics.

[10]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[11]  Cristina Has,et al.  Faculty of 1000 evaluation for Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. , 2018 .

[12]  P. Møller,et al.  Identification of genetic variants for clinical management of familial colorectal tumors , 2018, BMC Medical Genetics.

[13]  Roy G van Heesbeen,et al.  BUB1 Is Essential for the Viability of Human Cells in which the Spindle Assembly Checkpoint Is Compromised. , 2018, Cell reports.

[14]  Nathanael D. Moore,et al.  Inherited DNA Repair Defects in Colorectal Cancer , 2018, bioRxiv.

[15]  P. Møller,et al.  Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds , 2018, Hereditary cancer in clinical practice.

[16]  M. Dwyer,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  E. Letouzé,et al.  Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study , 2017, Genes, chromosomes & cancer.

[18]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[19]  O. Faiz,et al.  Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta‐analysis , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[20]  Ewout W Steyerberg,et al.  Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Amadori,et al.  Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer , 2017, Oncotarget.

[22]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[23]  K. Kast,et al.  Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer , 2016, Archives of Gynecology and Obstetrics.

[24]  A. V. van Kessel,et al.  The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery , 2016, Cellular Oncology.

[25]  P. Møller,et al.  Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database , 2016, Gut.

[26]  E. John,et al.  Multigene testing of moderate-risk genes: be mindful of the missense , 2016, Journal of Medical Genetics.

[27]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[28]  T. Frebourg,et al.  Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools , 2016, PLoS genetics.

[29]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[30]  E. Hovig,et al.  Automated amplicon design suitable for analysis of DNA variants by melting techniques , 2015, BMC Research Notes.

[31]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[32]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[33]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[35]  P. Devilee,et al.  Splicing analysis for exonic and intronic mismatch repair gene variants associated with Lynch syndrome confirms high concordance between minigene assays and patient RNA analyses , 2015, Molecular genetics & genomic medicine.

[36]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[37]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[38]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[39]  J. Chang-Claude,et al.  Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility , 2013, PloS one.

[40]  M. Woods,et al.  The InSiGHT database: utilizing 100 years of insights into Lynch Syndrome , 2013, Familial Cancer.

[41]  Jean-Philippe Vert,et al.  Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants , 2012, Human mutation.

[42]  W. Thilly,et al.  Separation principles of cycling temperature capillary electrophoresis , 2012, Electrophoresis.

[43]  J. Houwing-Duistermaat,et al.  MUTYH gene variants and breast cancer in a Dutch case–control study , 2012, Breast Cancer Research and Treatment.

[44]  Z. Herceg,et al.  Intensity‐dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles , 2011, Genes, chromosomes & cancer.

[45]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[46]  J. Tazi,et al.  A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects , 2008, Human mutation.

[47]  Qing Wang,et al.  Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing , 2006, Human mutation.

[48]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[49]  A. Sidow,et al.  Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. , 2005, Genome research.

[50]  D. Hinselwood,et al.  BRAF mutation detection and identification by cycling temperature capillary electrophoresis , 2005, Electrophoresis.

[51]  W. Grady.  Genetic testing for high-risk colon cancer patients. , 2003, Gastroenterology.

[52]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[53]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[54]  P. Møller,et al.  Breast cancer and other cancers in Norwegian families with ataxia‐telangiectasia , 1990, Genes, chromosomes & cancer.

[55]  McCollom Jh,et al.  The Discussion , 1897 .

[56]  P. Møller,et al.  Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families , 2017, Familial Cancer.

[57]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[58]  I. Hunter,et al.  Analysis of mutational spectra by denaturing capillary electrophoresis , 2008, Nature Protocols.

[59]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[60]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..